The Appropriateness of PSMA PET/CT in Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer Patients—Towards a Tumor Volume-Based Risk Stratification

Investigators reassessed the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer and validated the Prostate Cancer Network the Netherlands subclassification.